

Pluripotent Diagnostics (PDx) Announces Affordable Disease- and Patient-Specific Genetic Screening For Over 20 Diseases

The most advanced molecular genetics full-service company. Rates as low as \$249 per disease with over 1000 times more coverage than 23 and Me, and Ancestry.

SUNNYVALE, CALIFORNIA, UNITED STATES, June 28, 2021

/EINPresswire.com/ -- At Pluripotent Diagnostics (PDx), we believe in a world free of [genetic](#) disorders. Statistically, 7 out of 10 people die of a genetically related [disease](#). PDx proprietary patented solutions enable early genetic diagnoses at all ages to create customized person-specific therapeutic interventions. Ideally, this can improve and prolong lives, even prevent diseases altogether.



Pluripotent
Diagnostics

*Most advanced
molecular genetics
full-service company*

Pluripotent, Diagnostics, PDx, DNA, Rare Disease, Gene Therapy, Molecular Medicine, Disease, Alzheimer's, Dementia, Cancer

The holy grail of modern medicine is to customize treatments to health consumers. This next level of care consists of genetic analyses, pre-disease diagnostics, and ability to apply the results to create corrective therapies. From cradle to grave our genes govern our well-being. Many of the worst diseases ravaging our societies have a genetic component, from cancers, and neurodegenerative disorders like Alzheimer's, to heart and cardiovascular diseases. While companies like Ancestry do a reasonable job helping trace genealogies, individual genetic analysis is not readily available at an accessible cost, and incipient personalized treatments are few, and prohibitive. Further, the transplant industry is hobbled worldwide by the lack of suitable matching organs. Person-specific organ generation or cloning is currently non-existent for the general public outside of PDx.

Reading a genome and correcting its errors with personalized treatments is better than telling the future, and thanks to PDx, real. Person-specific early disease diagnostics and therapeutics can save health consumers from a multitude of genetic diseases. PDx utilizes bleeding-edge

technologies in the cross-disciplinary areas of artificial intelligence, genetics, and medicine to create a “genotype to phenotype” model. This novel technology, allows PDx to design the most sophisticated algorithms to identify disease likelihood, and therapeutic targeting for every health consumer. At this writing PDx is fulfilling orders for genome analyses from health consumers.

PDx is proud to announce the product launch of two services to the community: affordable single disease (multi-genic) next generation DNA sequencing (results are greater than 1000 times more detailed than 23 and Me, and Ancestry), and whole genome sequencing for the detection of any gene in your entire genome, with every DNA piece sequenced. These stringent methods are used to ensure we do not provide false-hope.

Current diseases covered: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Cardiovascular diseases, Pancreatic Cancer, Epilepsy, Breast Cancer, COPD (lung diseases), Non-Hodgkin’s Lymphoma, Multiple Sclerosis, Diabetes Type-2, Colon Cancer, and Amyotrophic Lateral Sclerosis/Lou Gehrig’s disease.

PDx is proudly located at California’s Molecular Medicine Research Institute in Silicon Valley.

To order a genetic kit, please go to PluripotentDiagnostics.com.

Prof. Sean James Miller

Pluripotent Diagnostics

[email us here](#)

Visit us on social media:

[Facebook](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/544979677>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.